Trials / Completed
CompletedNCT00515866
Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
A Phase I, Open Label, Study of the Safety and Tolerability of KU-0059436 in Combination With Gemcitabine in the Treatment of Patients With Advanced Solid Tumours
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with gemcitabine chemotherapy for the treatment of pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KU-0059436 (AZD2281)(PARP inhibitor) | oral |
| DRUG | Gemcitabine | intravenous injection |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2011-10-01
- Completion
- 2012-07-01
- First posted
- 2007-08-14
- Last updated
- 2013-12-20
Locations
4 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT00515866. Inclusion in this directory is not an endorsement.